CS251060B2 - 9-(hydroxyalkyl)purines' derivatives salts production method - Google Patents
9-(hydroxyalkyl)purines' derivatives salts production method Download PDFInfo
- Publication number
- CS251060B2 CS251060B2 CS796226A CS622679A CS251060B2 CS 251060 B2 CS251060 B2 CS 251060B2 CS 796226 A CS796226 A CS 796226A CS 622679 A CS622679 A CS 622679A CS 251060 B2 CS251060 B2 CS 251060B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- formula
- compound
- same meaning
- point
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C07D473/38—Sulfur atom attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/942,802 US4221909A (en) | 1978-09-15 | 1978-09-15 | P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS251060B2 true CS251060B2 (en) | 1987-06-11 |
Family
ID=25478620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS796226A CS251060B2 (en) | 1978-09-15 | 1979-09-14 | 9-(hydroxyalkyl)purines' derivatives salts production method |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4221909A (pl) |
| EP (1) | EP0009154B1 (pl) |
| JP (1) | JPS5547683A (pl) |
| KR (1) | KR840000552A (pl) |
| AT (1) | ATE1949T1 (pl) |
| AU (1) | AU527851B2 (pl) |
| CA (1) | CA1122217A (pl) |
| CS (1) | CS251060B2 (pl) |
| DD (1) | DD146049A5 (pl) |
| DE (1) | DE2964211D1 (pl) |
| DK (1) | DK149857C (pl) |
| ES (1) | ES484167A1 (pl) |
| FI (1) | FI68234C (pl) |
| GR (1) | GR74076B (pl) |
| HU (1) | HU182544B (pl) |
| IE (1) | IE48827B1 (pl) |
| IL (1) | IL58087A (pl) |
| IN (1) | IN153099B (pl) |
| MX (1) | MX6521E (pl) |
| NO (1) | NO152445C (pl) |
| NZ (1) | NZ191483A (pl) |
| PH (1) | PH16315A (pl) |
| PL (2) | PL124515B1 (pl) |
| PT (1) | PT70180A (pl) |
| RO (1) | RO77565A (pl) |
| YU (1) | YU41884B (pl) |
| ZA (1) | ZA793973B (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4340726A (en) * | 1980-03-14 | 1982-07-20 | Newport Pharmaceuticals International, Inc. | Esters |
| US4451478A (en) * | 1982-03-12 | 1984-05-29 | Newport Pharmaceuticals International, Inc. | Imidazole compounds |
| US5147636A (en) * | 1982-11-09 | 1992-09-15 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives and interferons |
| US4849411A (en) * | 1982-11-09 | 1989-07-18 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
| HUT36464A (en) * | 1983-05-24 | 1985-09-30 | Newport Pharmaceuticals | Process for producing erythro-4-amino-3-/2-hydroxy-3-alkyl/-imidazol-5-carboxamide |
| IT1215339B (it) * | 1987-01-14 | 1990-02-08 | Co Pharma Corp Srl | Procedimento per la preparazione di 9-(idrossialchil)-ipoxantine |
| US5091432A (en) * | 1990-03-28 | 1992-02-25 | Glasky Alvin J | 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use |
| US5614504A (en) * | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
| US6338963B1 (en) | 1994-07-25 | 2002-01-15 | Neotherapeutics, Inc. | Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| NZ291592A (en) | 1994-07-25 | 2001-03-30 | Michel P Rathbone | Use of carbon monoxide dependent guanylyl cyclase modulating purine derivative for treating neurological diseases |
| WO1997028803A1 (en) * | 1996-02-12 | 1997-08-14 | Cypros Pharmaceutical Corporation | Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits |
| US6303617B1 (en) | 1998-05-04 | 2001-10-16 | Neotherapeutics, Inc. | Serotonin-like 9-substituted hypoxanthine and methods of use |
| US6297226B1 (en) | 1999-10-15 | 2001-10-02 | Neotherapeutics, Inc. | Synthesis and methods of use of 9-substituted guanine derivatives |
| US6288069B1 (en) | 1999-11-16 | 2001-09-11 | Neotherapeutics, Inc. | Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| US6407237B1 (en) | 2001-02-21 | 2002-06-18 | Neotherapeutics, Inc. | Crystal forms of 9-substituted hypoxanthine derivatives |
| US6849735B1 (en) * | 2000-06-23 | 2005-02-01 | Merck Eprova Ag | Methods of synthesis for 9-substituted hypoxanthine derivatives |
| ES2385931T3 (es) | 2000-07-07 | 2012-08-03 | Spectrum Pharmaceuticals, Inc. | MÉTODOS PARA EL TRATAMIENTO DE NEUROPATíA PERIFÉRICA INDUCIDA POR UNA ENFERMEDAD Y AFECCIONES RELACIONADAS. |
| US6759427B2 (en) | 2001-04-20 | 2004-07-06 | Spectrum Pharmaceuticals, Inc. | Synthesis and methods of use of tetrahydroindolone analogues and derivatives |
| US20030055249A1 (en) * | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
| CA2540598C (en) * | 2003-10-03 | 2013-09-24 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
| US7585850B2 (en) * | 2004-02-10 | 2009-09-08 | Adenobio N.V. | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3215696A (en) * | 1965-11-02 | Substituted adenines -and preparation thereof | ||
| US3728450A (en) * | 1969-08-28 | 1973-04-17 | Newport Pharmaceuticals | Inosine derivatives |
| BE755361A (fr) * | 1969-08-28 | 1971-03-01 | Newport Pharmaceuticals | Derives de l'inosine |
| US3857940A (en) * | 1971-05-21 | 1974-12-31 | Newport Pharmaceuticals | Inosine derivatives |
| US3836656A (en) * | 1972-02-07 | 1974-09-17 | Sandoz Ag | Substituted purines as hypolipidemics |
| US3862189A (en) * | 1973-08-14 | 1975-01-21 | Warner Lambert Co | Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents |
| US4060616A (en) * | 1976-03-01 | 1977-11-29 | Burroughs Wellcome Co. | Purine derivatives with repeating unit |
| YU96177A (en) * | 1976-04-24 | 1982-08-31 | Wuelfing Johann A | Process for obtaining adenine derivatives |
-
1978
- 1978-09-15 US US05/942,802 patent/US4221909A/en not_active Expired - Lifetime
-
1979
- 1979-08-02 ZA ZA00793973A patent/ZA793973B/xx unknown
- 1979-08-22 IL IL58087A patent/IL58087A/xx unknown
- 1979-08-28 NO NO792792A patent/NO152445C/no unknown
- 1979-08-31 EP EP79103232A patent/EP0009154B1/en not_active Expired
- 1979-08-31 DE DE7979103232T patent/DE2964211D1/de not_active Expired
- 1979-08-31 IN IN618/DEL/79A patent/IN153099B/en unknown
- 1979-08-31 AT AT79103232T patent/ATE1949T1/de not_active IP Right Cessation
- 1979-09-04 AU AU50557/79A patent/AU527851B2/en not_active Ceased
- 1979-09-05 NZ NZ191483A patent/NZ191483A/xx unknown
- 1979-09-07 PH PH23010A patent/PH16315A/en unknown
- 1979-09-12 DD DD79215495A patent/DD146049A5/de not_active IP Right Cessation
- 1979-09-13 GR GR60030A patent/GR74076B/el unknown
- 1979-09-13 FI FI792849A patent/FI68234C/fi not_active IP Right Cessation
- 1979-09-14 CA CA000335702A patent/CA1122217A/en not_active Expired
- 1979-09-14 HU HU79NE619A patent/HU182544B/hu not_active IP Right Cessation
- 1979-09-14 IE IE1753/79A patent/IE48827B1/en not_active IP Right Cessation
- 1979-09-14 ES ES484167A patent/ES484167A1/es not_active Expired
- 1979-09-14 YU YU2245/79A patent/YU41884B/xx unknown
- 1979-09-14 JP JP11743979A patent/JPS5547683A/ja active Granted
- 1979-09-14 PT PT70180A patent/PT70180A/pt unknown
- 1979-09-14 PL PL1979226683A patent/PL124515B1/pl unknown
- 1979-09-14 CS CS796226A patent/CS251060B2/cs unknown
- 1979-09-14 PL PL1979218317A patent/PL119685B1/pl unknown
- 1979-09-14 DK DK385679A patent/DK149857C/da not_active IP Right Cessation
- 1979-09-15 KR KR1019790003209A patent/KR840000552A/ko unknown
- 1979-09-17 MX MX798386U patent/MX6521E/es unknown
- 1979-11-14 RO RO7998665A patent/RO77565A/ro unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS251060B2 (en) | 9-(hydroxyalkyl)purines' derivatives salts production method | |
| Gresser et al. | Increased survival in mice inoculated with tumor cells and treated with interferon preparations | |
| US4221794A (en) | Method of imparting immunomodulating and antiviral activity | |
| Ennis et al. | Cycloheximide: aspects of inhibition of protein synthesis in mammalian cells | |
| US4279892A (en) | Organogermanium induction of interferon production | |
| Djeu et al. | Augmentation of mouse natural killer activity and induction of interferon by tumor cells in vivo. | |
| Isaacs et al. | Studies on the mechanism of action of interferon | |
| JPH031310B2 (pl) | ||
| Hilleman | Prospects for the use of double-stranded ribonucleic acid (poly I: C) inducers in man | |
| JPH03504122A (ja) | 抗ウイルス・抗腫瘍・抗転移・免疫系増強ヌクレオシド類およびヌクレオチド類 | |
| JPH02117647A (ja) | 抗腫瘍性、抗ウイルス性、抗レトロウイルス性、抗乾癬性および殺虫性スペルミン誘導体 | |
| NL9000265A (nl) | Ethyl-6-broom-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-fenylthiomethylindool-3-carboxylaat-hydrochloride-monohydraat, werkwijze voor de bereiding ervan en een farmaceutisch preparaat dat deze stof bevat, met antivirale, interferon inducerende en immunomodulatoire effecten. | |
| Ilan et al. | Effects of colchicine on nucleic acid metabolism during metamorphosis of Tenebrio molitor L. and in some mammalian tissues | |
| CN101370783B (zh) | 9-氧代吖啶-10-乙酸和1-烷基氨基-1-脱氧多羟基化合物的盐和混合物、包含其的药物组合物以及治疗方法 | |
| AU636574B2 (en) | Method of using plant nucleoside derivatives for treatment of viral infections | |
| Gazdar et al. | Interferon inducers: enhancement of viral oncogenesis in mice and rats | |
| Renoux et al. | Isoprinosine as an immunopotentiator | |
| Miller et al. | Antiviral activity of carbobenzoxy di-and tripeptides on measles virus | |
| US5658886A (en) | Acridinone derivative, compositions containing same and a method for using same to treat Chlamydia trachomatis | |
| CA2174552A1 (en) | Flavin derivatives as anti-viral agents | |
| Spivack et al. | Dissociation of the inhibitory effects of 2-deoxy-D-glucose on Vero cell growth and the replication of herpes simplex virus | |
| DEGRæ et al. | Interferon induction in human cell cultures by small molecular inducers (tilorone and acridines) | |
| UA72286C2 (en) | Alkaline salts n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinsulfone)-n'-izonicotinoylhydrazide which can be used as antimicrobial and immunotropic agents, a method for the preparation thereof, use thereof as immunomodulator and pharmaceutical composition based thereon | |
| Huffman et al. | Lack of suppression of resistance factors to influenxa infections in mice pretreated with virazole | |
| World Health Organization | Interferon and other antiviral agents, with special reference to influenza: a memorandum |